Scolr Pharma Inc (SCLR)

Currency in USD
0.0001
0.0000(0.00%)
Closed·
Showing Scolr Pharma Inc historical data. For real-time data please try another search
Day's Range
0.00010.0001
52 wk Range
0.00000.0001
Key Statistics
Prev. Close
0.0001
Open
0.0001
Day's Range
0.0001-0.0001
52 wk Range
0-0
Volume
-
Average Volume (3m)
121.88K
1-Year Change
0%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Scolr Pharma Inc Company Profile

SCOLR Pharma, Inc., specialty pharmaceutical company, develops and commercializes prescription, over-the-counter, and nutritional products. The company uses its controlled delivery technology platform and develops water soluble and insoluble drugs, as well as high and low dose drugs; analgesic, cardiovascular, diabetes, anti-nausea, and pulmonary products; and dietary supplement products, including combinations of glucosamine and chondroitin, calcium, and other dietary products. Its lead drug product candidates include a 12 hour extended release formulation of ibuprofen, an analgesic for the treatment of pain, fever, and inflammation, which has completed Phase III clinical trial; and 12 hour Pseudoephedrine, a decongestant that is used to relieve sinus pressure related to allergies and common cold. The company is also developing IR Raloxifene for osteoporosis; ER Ondansetron, an anti-nausea drug; ER Phenylephrine a decongestant; and ER Niacin for cardiovascular disorders. In addition, it provides various formulation products for applications, including expectorant, analgesic, sleep aid, cough-cold, decongestant and antihistamine, hypercholesterolemia and hypertriglyceridemia, pain management, beta-blockers, Ca Channel blockers, Alzheimer’s disease, schizophrenia/bi-polar, diabetes, motion sickness, asthma, and bronchodilator. SCOLR Pharma, Inc. has a strategic alliance with Perrigo Company of South Carolina, Inc. for the manufacture, marketing, distribution, and sale of certain dietary supplements in the United States. The company was formerly known as SCOLR, Inc. and changed its name to SCOLR Pharma, Inc. in July 2004. SCOLR Pharma, Inc. was founded in 1983 and is headquartered in Redmond, Washington. As of October 3, 2016, SCOLR Pharma, Inc. operates as a subsidiary of Probi USA, Inc.

Employees
6

Earnings

Latest Release
Mar 27, 2019
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

SCLR Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.